Peripheral Neuropathy Trial, Recruiting (NCT07019233)

Peripheral Neuropathy Trial, Recruiting NCT07019233 Sponsor: Tianjin Medical University Cancer Institute and Hospital Condition: Peripheral Neuropathy

Printed from Voxsanity (voxsanity.com.au) — NCT07019233 — Data sourced from ClinicalTrials.gov. Verify directly with the trial site before attending. Not medical advice.

Back to Peripheral Neuropathy

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

"Who might be able to join this trial:

You have willingly agreed to take part and signed a consent form.
You are between 18 and 75 years old (any gender).
You are generally well enough to carry out daily activities with little to no limitation (confirm with trial site).
Your doctor has determined that a chemotherapy drug called albumin-paclitaxel is an appropriate treatment for you.
Your heart, lungs, liver, kidneys, and blood clotting are all working at a basically normal level.

Who may not be able to join:

You have previously received chemotherapy treatment.
You have been diagnosed with nerve damage or a nerve condition affecting your hands, feet, or other parts of the body (known as peripheral neuropathy).
You have been diagnosed with certain other health conditions alongside your current illness, such as diabetes (confirm with trial site for full list of conditions).

Important: Always verify eligibility with the trial site directly before applying."

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.

Last synced 12 July 2026

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Phone: （022）65150123-8212

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Voxsanity

Clinical trials and treatments, explained plainly · voxsanity.com.au

Date:

To: My Doctor

Re: Clinical trial enquiry

I am writing to enquire about the following clinical trial which may be relevant to my care:

Trial: NCT07019233

Sponsor: Tianjin Medical University Cancer Institute and Hospital

Phase: Not Applicable

Status: Recruiting

Condition: Peripheral Neuropathy

Trial contact: （022）65150123-8212

More information: https://clinicaltrials.gov/study/NCT07019233

Eligibility summary (AI generated)

Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

"Who might be able to join this trial:

You have willingly agreed to take part and signed a consent form.
You are between 18 and 75 years old (any gender).
You are generally well enough to carry out daily activities with little to no limitation (confirm with trial site).
Your doctor has determined that a chemotherapy drug called albumin-paclitaxel is an appropriate treatment for you.
Your heart, lungs, liver, kidneys, and blood clotting are all working at a basically normal level.

Who may not be able to join:

You have previously received chemotherapy treatment.
You have been diagnosed with nerve damage or a nerve condition affecting your hands, feet, or other parts of the body (known as peripheral neuropathy).
You have been diagnosed with certain other health conditions alongside your current illness, such as diabetes (confirm with trial site for full list of conditions).

Important: Always verify eligibility with the trial site directly before applying."

Access in Australia: A treatment being studied in a clinical trial is generally not yet listed on the PBS. Where a medicine is not approved or not available through a trial, the TGA Special Access Scheme may allow a doctor to access unapproved therapeutic goods for individual patients. See voxsanity.com.au/sas-navigator/ for a plain English explainer.

This information was sourced from ClinicalTrials.gov via Voxsanity (data last synced 12 July 2026). It is not medical advice. Please verify the trial's current status directly with the trial site before acting.

Trial details

Status

Recruiting

Phase

Not Applicable

Sponsor

Tianjin Medical University Cancer Institute and Hospital

Registry

ClinicalTrials.gov

Start date

1 September 2024

Est. completion

31 December 2025

Where this trial is recruiting

🇨🇳 China

Primary endpoints

CIPN-related symptoms, as assessed by changes in tactile sensitivity at pretreatment baseline CIPN incidence.The Patient Neurotoxicity Questionnaire (PNQ) was used to assess and grade the incidence and severity of CIPN.

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 12 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov